Answers are grounded in this paper and cite their sources.
Somatomedin-C (SM-C) and insulin-like growth factor I (IGF-I) produced identical curves of competition in a RIA for SM-C, and in placental cell membrane receptor assays for SM-C and insulin. Somatomedin-A (SM-A), insulin-like growth factor II (IGF-II) and two forms of multiplication stimulating activity (MSA) were less than 5% as potent as SM-C/IGF-I in the RIA and less than 50% that of SM-C/IGFi in the SM-C receptor assay. In the insulin receptor assay, IGF-II and MSA III-2 were much more potent than SM-C/IGF-I. The present data suggest that SM-C and IGF-I are functionally identical substances.
No takes yet. Share an insight, caveat, or question.
Wyk et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: